NI 301
Alternative Names: NI-301Latest Information Update: 28 May 2021
At a glance
- Originator Neurimmune Therapeutics
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Prealbumin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyloid polyneuropathy; Neurological disorders
Highest Development Phases
- No development reported Cardiomyopathies; Neurological disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cardiomyopathies in Switzerland
- 28 May 2021 No recent reports of development identified for preclinical development in Neurological-disorders in Switzerland
- 26 Apr 2017 NI 301 is available for licensing as of 26 Apr 2017. http://www.neurimmune.com/company/about-neurimmune.html